Axonex AI Group Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AXNX research report →
Price Chart
About the company
Axonex AI Group Limited is a holding company, which engages in the provision of interior design and fit works. It offers design services including layout plans and sketches presented in the form of 3D technical drawing and design, and fit out services. It operates through the Design and Fit Out Services, and Design Only Services segments.
- CEO
- Hoi Lung Chan
- IPO
- 2025
- Employees
- 36
- HQ
- Hong Kong, HK
Get TickerSpark's AI analysis on AXNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.04M
- P/E
- -0.69
- PEG
- -0.05
- P/S
- 18.73
- P/B
- 0.28
- EV/EBITDA
- -4.25
- Div Yield
- 0.00%
- Gross Margin
- 10.92%
- Op Margin
- -450.34%
- Net Margin
- -449.90%
- ROE
- -67.18%
- ROIC
- -30.29%
Latest fiscal year · YoY change
- Revenue
- $293.51K-91.0%
- Gross Profit
- $81.88-100.0%
- Op Income
- $-1,305,392
- Net Income
- $-1,321,696+9.5%
- EPS
- $-1.33+17.4%
- OCF Growth
- +73.7%
- FCF Growth
- +67.5%
- 52W High
- $18.35
- 52W Low
- $0.68
- 50D MA
- $1.52
- 200D MA
- $5.32
- Beta
- 3.30
- RSI (14)
- 35
- Avg Volume
- 2.01M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Axonics delivered 32% Q3 revenue growth, raised full-year guidance, and said its business continues to benefit from strong SNM penetration, Bulkamid momentum, and improving margins.· October 30, 2023
- Q3 revenue was $93.1 million, up 32% year over year, with SNM revenue of $73.9 million (+30%) and Bulkamid revenue of $19.2 million (+42%).
- Gross margin improved to 74.2% from 72.8% a year ago, and adjusted EBITDA was $14 million versus $3.3 million last year.
- Full-year 2023 revenue guidance was raised to $362 million from $358 million, implying 32% growth vs. 2022.
- Management said Q4 gross margin should be 74% to 75% and Q4 operating expenses about $79 million.
- The company emphasized continued gains at existing accounts, DTC-driven awareness, and upcoming product catalysts including F15 approvals internationally and a new external trial system.
Axonics reported third-quarter 2023 net revenue of $93.1 million, up 32% year over year. SNM revenue was $73.9 million, up 30% year over year, and Bulkamid revenue was $19.2 million, up 42% year over year. Gross profit was $69.1 million with gross margin of 74.2%, versus 72.8% in the prior-year period. Net income was $3.9 million versus a net loss of $16.3 million a year ago, and adjusted EBITDA was $14 million versus $3.3 million last year. Cash, cash equivalents and short-term investments were $344.7 million as of September 30, 2023. For full-year 2023, management raised revenue guidance to $362 million from $358 million, including SNM revenue of $288.5 million and Bulkamid revenue of $73.5 million; both imply 30% and 42% growth, respectively, versus 2022. For Q4, gross margin is expected to be 74% to 75% and operating expenses about $79 million.
Raymond Cohen framed the quarter as another period of strong execution and said growth is being driven by both deeper penetration at existing accounts and new account additions. He pointed to high-teen growth in existing U.S. customer procedural volumes, more than 10,000 qualified DTC leads per month, and growing interest in Bulkamid and SNM as signs of an underserved market. His tone was upbeat and confident, with repeated emphasis that Axonics is the innovator in the space and has meaningful runway ahead.
Kari Keese highlighted the financial leverage in the model, noting Q3 gross margin of 74.2% and first-nine-months gross margin of 74.7%. She said Q4 gross margin should run 74% to 75% as yield and supply-chain issues have improved, while Q4 operating expenses should be about $79 million, consistent with the prior full-year adjusted operating expense guide of $280 million. She also noted cash, cash equivalents and short-term investments of $344.7 million, up $13.2 million sequentially, and said Q3 net income of $3.9 million was aided by just over $4 million of interest income.
Analysts focused on the drivers of strong existing-account growth, margin expansion, 2024 EBITDA leverage, international SNM opportunity, DTC effectiveness, and whether Bulkamid and SNM can be used more strategically together. Management said growth is being driven by a mix of better office workflow, clinical specialist support, more awareness from DTC, and physicians recognizing better outcomes; it also said DTC is helpful but not the main driver. On international SNM, management said approval of the non-rechargeable F15 system is important before the company can compete more aggressively, and on margins it said 75% gross margin is not viewed as a ceiling. On M&A, Cohen said Axonics is always “for sale every minute of every day,” but the company’s real focus is execution and selective strategic additions.
The call showed broad momentum: revenue, margins, adjusted EBITDA, and cash all moved in the right direction, and management raised full-year revenue guidance. The company believes it is still early in market penetration, with strong growth at existing accounts, expanding product mix, and upcoming catalysts such as international F15 approvals and new product launches.
Management repeatedly noted that international SNM growth remains limited until regulatory approvals come through, and the timing is uncertain. Q4 operating expenses are set to rise, gross margin can be choppy quarter to quarter, and management said it wants to wait until early 2024 to give formal 2024 guidance. The company also acknowledged that DTC and account penetration take time to work through the care pathway and that displacing a long-entrenched competitor is still a multi-year effort.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- —
- Shares Outstanding
- 6.08M
- Float Shares
- 3.49M
of shares held by institutions
238 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 4.34M | ▲ 55.63K |
| Putnam Investments LLC | 239.36K | ▲ 62.67K |
| Segantii Capital Management Ltd | 165.00K | ▲ 165.00K |
| Credit Suisse AG/ | 99.56K | ▼ 884.50K |
| Eisler Capital (Uk) Ltd. | 98.47K | ▲ 98.47K |
| Endurant Capital Management LP | 24.87K | ▲ 24.87K |
| Flow State Investments, L.P. | 19.00K | ▲ 19.00K |
| Crystalline Management Inc. | 10.00K | ▼ 20.00K |
| Btg Pactual Global Asset Management Ltd | 10.00K | ▲ 10.00K |
| Atonra Partners | 8.10K | ▼ 736 |
| Fort Pitt Capital Group, LLC | 5.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Chan Hoi Lung | buy | 211,879 |
| Mar 18, 26 | Siu Chun Pong Raymond | other | 0 |
| Mar 18, 26 | Wong Kai Wai | other | 0 |
| Mar 18, 26 | Cheng Sze Ki | other | 0 |
| Mar 18, 26 | Chan Hoi Lung | other | 0 |
| Mar 18, 26 | Chan Hoi Lung | other | 0 |
| Mar 18, 26 | Xiu Xunze | other | 0 |
| Mar 18, 26 | Ku Cheong Shing | other | 0 |
| Mar 18, 26 | Ku Cheong Shing | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AXNX coverage
Recent articles, reports, and earnings notes.
No research on AXNX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AXNX report →Axonex AI Group Limited Announces 2-for-5 Reverse Stock Split
globenewswire.com · Oct 20
Axonex AI Group Joins FLAIR's Embodied AI International Applications Hub and Launches Education Humanoid TOMO
globenewswire.com · Oct 15
Axonex AI Group Limited (NASDAQ: AXNX) Solidifies Transformation into an AI and Robotics-Focused Company
globenewswire.com · Oct 9
Mint Enters into OEM Supply and License Agreement with Ireland-based Centridex to Expand into Europe
globenewswire.com · Oct 7
Mint Incorporation Limited (NASDAQ:MIMI) Short Interest Update
defenseworld.net · Oct 1
Mint Announces Rice AI's Licensing Collaboration with Pudgy Penguins to Launch Co-Branded "Blue Pengu Minibot"
globenewswire.com · Sep 15
Mint's Majority Owned Subsidiary Rice Robotics Hong Kong Enters into Non-Exclusive Framework Cooperation Agreement with Vengine to Scale Manufacturing Network
globenewswire.com · Sep 10
Mint Signed MOU with Edvance Innovation Limited to Expand into the Middle East and North Africa Education Robotics Market Through Distribution Partnership
globenewswire.com · Sep 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.